News Lilly takes on Vertex in non-opioid pain with SiteOne buy Lilly buys SiteOne in a $1bn deal that would give it a rival to Vertex's approved painkiller Journavx, and a partnership on another programme.
News Novo Holdings leads $100m round for novel painkiller biotech SiteOne Therapeutics has completed a $100 million third-round financing that will support clinical trials of its non-opioid painkiller.
News Sobi adds rare lymphoma drug with $580m Innate tie-up Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.